JP2012502915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502915A5 JP2012502915A5 JP2011527044A JP2011527044A JP2012502915A5 JP 2012502915 A5 JP2012502915 A5 JP 2012502915A5 JP 2011527044 A JP2011527044 A JP 2011527044A JP 2011527044 A JP2011527044 A JP 2011527044A JP 2012502915 A5 JP2012502915 A5 JP 2012502915A5
- Authority
- JP
- Japan
- Prior art keywords
- epilepsy
- pharmaceutically acceptable
- acceptable salts
- therapeutic agent
- focal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 208000002877 Epileptic Syndromes Diseases 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- 208000003078 Generalized Epilepsy Diseases 0.000 claims 3
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000024658 Epilepsy syndrome Diseases 0.000 claims 2
- 206010061334 Partial seizures Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 201000007186 focal epilepsy Diseases 0.000 claims 2
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 claims 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims 1
- 208000034308 Grand mal convulsion Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 1
- 201000009006 Partial Sensory Epilepsy Diseases 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- 208000006633 Tonic-Clonic Epilepsy Diseases 0.000 claims 1
- 208000003554 absence epilepsy Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000002566 clonic effect Effects 0.000 claims 1
- 229960001985 dextromethorphan Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims 1
- 201000002933 epilepsy with generalized tonic-clonic seizures Diseases 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 201000008912 partial motor epilepsy Diseases 0.000 claims 1
- 201000005070 reflex epilepsy Diseases 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 229940125794 sodium channel blocker Drugs 0.000 claims 1
- 239000003195 sodium channel blocking agent Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9694008P | 2008-09-15 | 2008-09-15 | |
| US61/096,940 | 2008-09-15 | ||
| US18320909P | 2009-06-02 | 2009-06-02 | |
| US61/183,209 | 2009-06-02 | ||
| PCT/US2009/056988 WO2010031054A1 (en) | 2008-09-15 | 2009-09-15 | Compositions and methods for treating epilepsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012502915A JP2012502915A (ja) | 2012-02-02 |
| JP2012502915A5 true JP2012502915A5 (enExample) | 2013-05-16 |
Family
ID=42005540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527044A Pending JP2012502915A (ja) | 2008-09-15 | 2009-09-15 | てんかんを治療する組成物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20110172262A1 (enExample) |
| EP (1) | EP2340254B8 (enExample) |
| JP (1) | JP2012502915A (enExample) |
| WO (1) | WO2010031054A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101424514B1 (ko) | 2013-01-02 | 2014-07-31 | 건국대학교 산학협력단 | 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도 |
| GB2530001B (en) * | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| WO2017021951A1 (en) * | 2015-08-03 | 2017-02-09 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Blood-brain-barrier permeability modulators and uses thereof |
| US11045462B2 (en) | 2016-06-14 | 2021-06-29 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods for treating neurological conditions and exposure to nerve agents |
| US11839604B2 (en) | 2016-12-31 | 2023-12-12 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
| PT3813802T (pt) | 2018-06-27 | 2025-01-15 | Arx Llc | Formulações de películas contendo dexmedetomidina e métodos de produção das mesmas |
| WO2021016112A2 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| EP4297871A4 (en) * | 2021-02-26 | 2025-01-01 | BioXcel Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR TREATING AGITATION |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3847770A (en) | 1972-04-10 | 1974-11-12 | Continental Can Co | Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates |
| US3959470A (en) | 1972-11-28 | 1976-05-25 | Mikhail Davidovich Mashkovsky | Psychotropic medicinal preparation |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4769027A (en) | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4687610A (en) | 1986-04-30 | 1987-08-18 | E. I. Du Pont De Neumours And Company | Low crystallinity polyester yarn produced at ultra high spinning speeds |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5627165A (en) * | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5354566A (en) | 1993-06-02 | 1994-10-11 | Kraft General Foods, Inc. | Preparation of yeast-leavened dough crusts |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5602124A (en) | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| RU2140417C1 (ru) * | 1995-10-17 | 1999-10-27 | Институт физиологически активных веществ РАН | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения |
| RU2106864C1 (ru) * | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
| IL133077A0 (en) | 1999-01-29 | 2001-03-19 | Pfizer Prod Inc | Azithromycin combination for emesis control in dogs |
| US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US6383764B1 (en) * | 2000-04-28 | 2002-05-07 | The Regents Of The University Of California | Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP) |
| US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| JP2005533009A (ja) | 2002-03-28 | 2005-11-04 | イーライ・リリー・アンド・カンパニー | ピペラジン置換されたアリールベンゾジアゼピン類およびそのドーパミン受容体アンタゴニストとしての精神病性障害の処置のための使用 |
| US20050171032A1 (en) | 2002-04-11 | 2005-08-04 | Children's Medical Center Corporation | Methods for the treatment of cancer |
| US20040102525A1 (en) | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| GB0307067D0 (en) | 2002-12-17 | 2003-04-30 | Aventis Pharma Inc | Use of thiazolobenzoheterocycles for treating multiple sclerosis |
| US20050065219A1 (en) | 2003-03-27 | 2005-03-24 | Lipton Stuart A. | Treatment of demyelinating conditions |
| JPWO2004098638A1 (ja) | 2003-05-06 | 2006-07-13 | 小野薬品工業株式会社 | エフェクター細胞機能阻害剤 |
| WO2005009342A2 (en) | 2003-07-16 | 2005-02-03 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| US7060723B2 (en) * | 2003-08-29 | 2006-06-13 | Allergan, Inc. | Treating neurological disorders using selective antagonists of persistent sodium current |
| US20050245460A1 (en) * | 2004-02-13 | 2005-11-03 | Meyerson Laurence R | Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders |
| RU2281085C2 (ru) | 2004-05-25 | 2006-08-10 | Закрытое акционерное общество "Мастерлек" | Антидепрессивные лекарственные средства для парентерального применения на основе сульфонатных солей пирлиндола |
| EP1688161A1 (en) | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| US7790712B2 (en) | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| EP1910361A2 (en) | 2005-07-28 | 2008-04-16 | Brystol-Myers Squibb Company | Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists |
| US8802707B2 (en) | 2005-07-31 | 2014-08-12 | Trevor Gordon Marshall | Method of treating and/or preventing cancers using Sartans and/or Statins to modulate VDR, and/or PPAR, and/or GCR and/or CB1 receptors; in conjunction with certain bacteriostatic antibiotics |
| US8868172B2 (en) * | 2005-12-28 | 2014-10-21 | Cyberonics, Inc. | Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders |
| JP2010501559A (ja) | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | 黒色腫の再発を予防するまたは遅らせるのに使用するためのビス（チオヒドラジドアミド） |
| CA2664099A1 (en) | 2006-09-20 | 2008-03-27 | Medivation Neurology, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis (als) |
| US20080108574A1 (en) * | 2006-09-27 | 2008-05-08 | Braincells, Inc. | Melanocortin receptor mediated modulation of neurogenesis |
| AU2007309390A1 (en) * | 2006-10-27 | 2008-05-02 | Medivation Neurology, Inc. | Methods and combination therapies for treating Alzheimer's disease |
| TW200848063A (en) | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| US20100178277A1 (en) | 2007-05-25 | 2010-07-15 | Medivation Neurology, Inc. | Methods and compositions for stimulating cells |
| WO2008156654A2 (en) | 2007-06-15 | 2008-12-24 | Massachusetts Institute Of Technology | Cytoskeleton modulators for treating metabolic disorders |
| US20110111014A1 (en) | 2007-06-26 | 2011-05-12 | Parkinson's Institute | Methods and compositions for treatment of neurological disorders |
| EP2085120A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance |
| WO2009135091A1 (en) | 2008-04-30 | 2009-11-05 | Medivation Technologies, Inc. | Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions |
| EP2355660A4 (en) | 2008-10-13 | 2012-05-02 | Biovista Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
| WO2010068867A1 (en) | 2008-12-11 | 2010-06-17 | Biovista, Inc. | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
-
2009
- 2009-09-15 WO PCT/US2009/056988 patent/WO2010031054A1/en not_active Ceased
- 2009-09-15 US US13/063,873 patent/US20110172262A1/en not_active Abandoned
- 2009-09-15 EP EP09813797.9A patent/EP2340254B8/en not_active Not-in-force
- 2009-09-15 JP JP2011527044A patent/JP2012502915A/ja active Pending
-
2014
- 2014-04-14 US US14/251,819 patent/US20150133488A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,362 patent/US11389435B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502915A5 (enExample) | ||
| HRP20200600T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
| JP2010077141A5 (enExample) | ||
| JP2016501828A5 (enExample) | ||
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| JP2010174019A5 (enExample) | ||
| JP2009506117A5 (enExample) | ||
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| JP2012255026A5 (enExample) | ||
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| JP2013519675A5 (enExample) | ||
| JP2015512406A5 (enExample) | ||
| JP2009525343A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| JP2011527299A5 (enExample) | ||
| HRP20201316T1 (hr) | Novi modulatori receptora sfingozin-fosfata | |
| JP2016517888A5 (enExample) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| BRPI0807285A2 (pt) | "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto" | |
| JP2009537554A5 (enExample) | ||
| MA33463B1 (fr) | Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| RU2014115287A (ru) | Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения | |
| WO2011159100A2 (ko) | 항암 활성을 나타내는 약제학적 조성물 |